PEP Biologic™
Diabetic Foot Ulcers
Key Facts
About Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileAbout Intent Biologics
Intent Biologics is an early-stage biotech leveraging proprietary exosome technology derived from over two decades of Mayo Clinic research and RION's biomanufacturing expertise. The company's core asset, PEP Biologic™, is a topical biologic delivering concentrated exosomes to promote tissue healing and modulate immune responses, targeting large, underserved markets in chronic wounds and autoimmune dermatology. As a private, pre-revenue company, Intent is advancing its pipeline through preclinical and clinical development, positioning itself at the forefront of the emerging exosome therapeutics field.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers Drugs
| Drug | Company | Phase |
|---|---|---|
| TOP-N53 | Topadur Pharma | Phase 2 |
| IonoJet™ | Origin | Phase 3 |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| CXCL12 Formulation for DFU | ViCapsys | Pre-clinical |
| CYP-006 | Cynata Therapeutics | Preclinical |
| NovoSorb BTM | PolyNovo | Clinical Investigation |
| EPIFIX® / AMNIOFIX® | MiMedx Group | Post-Market Study |
| Dermagraft | Organogenesis | Approved/Commercial |